<unk> is metabolized mainly by CYP1A enzymes. As such, inhibitors and inducers of CYP1A enzymes, such as CYP1A2, can modify<unk> metabolism and exposure. As an example, the CYP1A2 and CYP2C19 inhibitor fluvoxamine increases<unk> peak levels by 12-fold and overall exposure by 17-fold and this combination should be avoided. CYP1A2 inducers like cigarette smoking, carbamazepine, and rifampicin may reduce<unk> exposure due to induction of CYP1A2. In those taking warfarin, some evidence suggests there may exist a potentiating interaction, increasing the anticoagulant effect of warfarin and the risk of bleeding.
Melatonin 
Etoperidone
Sertindole
Tropisetron
Zolpidem
Cilansetron
Chloracyzine
Alosetron